Minerva Neurosciences (NERV) Competitors $2.25 +0.07 (+3.21%) Closing price 09/15/2025 03:59 PM EasternExtended Trading$2.24 0.00 (-0.22%) As of 09/15/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NERV vs. ALXO, ANL, CELU, GNTA, MNOV, GANX, ABVC, IMMX, HOWL, and BTAIShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include ALX Oncology (ALXO), Adlai Nortye (ANL), Celularity (CELU), Genenta Science (GNTA), MediciNova (MNOV), Gain Therapeutics (GANX), ABVC BioPharma (ABVC), Immix Biopharma (IMMX), Werewolf Therapeutics (HOWL), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. Its Competitors ALX Oncology Adlai Nortye Celularity Genenta Science MediciNova Gain Therapeutics ABVC BioPharma Immix Biopharma Werewolf Therapeutics BioXcel Therapeutics ALX Oncology (NASDAQ:ALXO) and Minerva Neurosciences (NASDAQ:NERV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Which has better valuation & earnings, ALXO or NERV? ALX Oncology is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$134.85M-$2.20-0.48Minerva NeurosciencesN/AN/A$1.44M$1.481.52 Do institutionals & insiders believe in ALXO or NERV? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 21.0% of ALX Oncology shares are held by company insiders. Comparatively, 8.6% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is ALXO or NERV more profitable? Minerva Neurosciences' return on equity of -41.35% beat ALX Oncology's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -115.67% -84.82% Minerva Neurosciences N/A -41.35%31.37% Do analysts recommend ALXO or NERV? ALX Oncology currently has a consensus price target of $3.30, indicating a potential upside of 214.29%. Minerva Neurosciences has a consensus price target of $5.00, indicating a potential upside of 122.22%. Given ALX Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe ALX Oncology is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, ALXO or NERV? ALX Oncology has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Does the media favor ALXO or NERV? In the previous week, ALX Oncology had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for ALX Oncology and 2 mentions for Minerva Neurosciences. ALX Oncology's average media sentiment score of 0.65 beat Minerva Neurosciences' score of 0.45 indicating that ALX Oncology is being referred to more favorably in the media. Company Overall Sentiment ALX Oncology Positive Minerva Neurosciences Neutral SummaryALX Oncology beats Minerva Neurosciences on 8 of the 13 factors compared between the two stocks. Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$2.56B$5.79B$10.18BDividend YieldN/A57.23%5.73%4.61%P/E Ratio1.5223.2874.8626.39Price / SalesN/A692.88543.67125.97Price / Cash10.4327.5625.8129.91Price / Book-0.615.4013.256.28Net Income$1.44M$32.95M$3.29B$270.38M7 Day Performance4.65%-0.53%0.07%1.89%1 Month PerformanceN/A4.23%4.60%6.01%1 Year Performance-23.08%-2.81%72.95%25.26% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences3.7648 of 5 stars$2.25+3.2%$5.00+122.2%-23.7%$0.00N/A1.529Short Interest ↑ALXOALX Oncology3.5391 of 5 stars$1.11-9.0%$3.30+197.3%-52.7%$65.33MN/A-0.5040Positive NewsANLAdlai Nortye1.9694 of 5 stars$1.70-2.9%$9.00+429.4%-22.9%$64.57M$5M0.00127News CoveragePositive NewsShort Interest ↓Gap UpCELUCelularity1.6939 of 5 stars$2.11-12.4%$6.00+184.4%-21.8%$64.33M$54.22M-0.66220GNTAGenenta Science2.7668 of 5 stars$3.49-0.3%$25.00+616.3%-22.6%$64.02MN/A0.007Gap UpMNOVMediciNova2.1633 of 5 stars$1.26-2.3%$7.00+455.6%-31.9%$63.27M$134.60K-5.0410GANXGain Therapeutics2.9308 of 5 stars$1.75-0.6%$8.00+357.1%+11.9%$63.27M$50K-2.7820Positive NewsGap UpABVCABVC BioPharma0.6861 of 5 stars$2.72+2.6%N/A+313.5%$62.39M$510K-16.0030IMMXImmix Biopharma3.0898 of 5 stars$2.17+0.9%$7.00+222.6%+12.4%$61.99MN/A-2.829News CoverageAnalyst ForecastShort Interest ↑HOWLWerewolf Therapeutics4.0065 of 5 stars$1.33-1.5%$8.00+501.5%-38.9%$61.73M$1.88M-0.8140BTAIBioXcel Therapeutics3.9554 of 5 stars$4.23+11.6%$39.75+839.7%-70.9%$60.67M$2.27M-0.3390Analyst ForecastShort Interest ↑ Related Companies and Tools Related Companies ALX Oncology Alternatives Adlai Nortye Alternatives Celularity Alternatives Genenta Science Alternatives MediciNova Alternatives Gain Therapeutics Alternatives ABVC BioPharma Alternatives Immix Biopharma Alternatives Werewolf Therapeutics Alternatives BioXcel Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NERV) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
